scholarly journals Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers

2016 ◽  
Vol 23 (10) ◽  
pp. T69-T84 ◽  
Author(s):  
Roger L Milne ◽  
Antonis C Antoniou

Pathogenic mutations inBRCA1andBRCA2are associated with high risks of breast and ovarian cancer. However, penetrance estimates for mutation carriers have been found to vary substantially between studies, and the observed differences in risk are consistent with the hypothesis that genetic and environmental factors modify cancer risks for women with these mutations. Direct evidence that this is the case has emerged in the past decade, through large-scale international collaborative efforts. Here, we describe the methodological challenges in the identification and characterisation of these risk-modifying factors, review the latest evidence on genetic and lifestyle/hormonal risk factors that modify breast and ovarian cancer risks for women withBRCA1andBRCA2mutations and outline the implications of these findings for cancer risk prediction. We also review the unresolved issues in this area of research and identify strategies of clinical implementation so that women withBRCA1andBRCA2mutations are no longer counselled on the basis of ‘average’ risk estimates.

2013 ◽  
Vol 21 (12) ◽  
pp. 1361-1368 ◽  
Author(s):  
Marion Drüsedau ◽  
Jos C Dreesen ◽  
Inge Derks-Smeets ◽  
Edith Coonen ◽  
Ron van Golde ◽  
...  

2010 ◽  
Vol 20 (Suppl 2) ◽  
pp. S31-S33 ◽  
Author(s):  
Ami Fishman

Knowledge of the potential association of parity, breastfeeding, and infertility treatment on breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers is important and should be a crucial part of genetic counseling. The discussion of parity and clinical management of infertility in these women is complex, and patient preferences should be considered. Ideally, these preferences should be informed by accurate information on the risks and benefits of the interventions considered. However, this important subject has been investigated in a relatively small number of studies, thus, the existing data remain somewhat limited, and the estimated risk of cancer in BRCA mutation carriers is imprecise.


2009 ◽  
Vol 119 (1) ◽  
pp. 221-232 ◽  
Author(s):  
Roger L. Milne ◽  
Ana Osorio ◽  
Teresa Ramón y Cajal ◽  
Montserrat Baiget ◽  
Adriana Lasa ◽  
...  

2010 ◽  
Vol 19 (11) ◽  
pp. 2859-2868 ◽  
Author(s):  
Christoph Engel ◽  
Beatrix Versmold ◽  
Barbara Wappenschmidt ◽  
Jacques Simard ◽  
Douglas F. Easton ◽  
...  

2014 ◽  
Vol 24 (1) ◽  
pp. 308-316 ◽  
Author(s):  
Paolo Peterlongo ◽  
Jenny Chang-Claude ◽  
Kirsten B. Moysich ◽  
Anja Rudolph ◽  
Rita K. Schmutzler ◽  
...  

2021 ◽  
Vol 132 ◽  
pp. S357-S358
Author(s):  
Shana Kim ◽  
Jan Lubinski ◽  
Tomasz Huzarski ◽  
Pal Moller ◽  
Susan Armel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document